Biomarin Pharmaceutical Inc
NASDAQ: BMRN
$66.13
-$0.24 (-0.4%)
Closing Price on November 12, 2024
BMRN Articles
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Published:
Last Updated:
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
Published:
Last Updated:
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
Published:
Last Updated:
24/7 Wall St. has collected four companies big FDA decisions coming up in the first quarter of 2016 and added some color.
Published:
Last Updated:
A new Jefferies research report focuses on some biotech and specialty pharmaceutical stocks that have had some headline and clinical issues muddy the waters.
Published:
Last Updated:
Wednesday's top analyst upgrades, downgrades and initiations include Apple, Bluebird, Exxon Mobil, Kinder Morgan, Kinross Gold, Lending Club and Perrigo.
Published:
Last Updated:
This week the Jefferies analysts are positive on companies that took a shot price-wise last week and may be offering an even better entry point for investors.
Published:
Last Updated:
24/7 Wall St. tracked 15 fresh analyst calls in this past week alone in which analysts were calling for upside of almost 50% or more.
Published:
Last Updated:
Friday's top analyst upgrades, downgrades and initiations include Abbott Labs, BioMarin Pharmaceutical, CBS, Cisco, GameStop, Petrobras, Sirius XM, SunPower and Yelp.
Published:
Last Updated:
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
Published:
A report on Wednesday from Janney Capital Markets has targeted several iotech bcompanies it believes are now grossly oversold.
Published:
In a recent research report, Jefferies highlighted three top biotech companies that are very tempting buys now.
Published:
Now is the time to really review portfolios and replace momentum winners with earnings growth leaders. The Cowen Focus Call stocks are just the ticket.
Published:
SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving clinical and FDA catalysts during the remainder of 2015.
Published:
A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.
Published: